Hydrocortisone plus fludrocortisone for adults with septic shock.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Septic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock. METHODS: In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included mortality at intensive care unit (ICU) discharge and hospital discharge and at day 28 and day 180 and the number of days alive and free of vasopressors, mechanical ventilation, or organ failure. After drotrecogin alfa (activated) was withdrawn from the market, the trial continued with a two-group parallel design. The analysis compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo group). RESULTS: Among the 1241 patients included in the trial, the 90-day mortality was 43.0% (264 of 614 patients) in the hydrocortisone-plus-fludrocortisone group and 49.1% (308 of 627 patients) in the placebo group (P=0.03). The relative risk of death in the hydrocortisone-plus-fludrocortisone group was 0.88 (95% confidence interval, 0.78 to 0.99). Mortality was significantly lower in the hydrocortisone-plus-fludrocortisone group than in the placebo group at ICU discharge (35.4% vs. 41.0%, P=0.04), hospital discharge (39.0% vs. 45.3%, P=0.02), and day 180 (46.6% vs. 52.5%, P=0.04) but not at day 28 (33.7% and 38.9%, respectively; P=0.06). The number of vasopressor-free days to day 28 was significantly higher in the hydrocortisone-plus-fludrocortisone group than in the placebo group (17 vs. 15 days, P<0.001), as was the number of organ-failure-free days (14 vs. 12 days, P=0.003). The number of ventilator-free days was similar in the two groups (11 days in the hydrocortisone-plus-fludrocortisone group and 10 in the placebo group, P=0.07). The rate of serious adverse events did not differ significantly between the two groups, but hyperglycemia was more common in hydrocortisone-plus-fludrocortisone group. CONCLUSIONS: In this trial involving patients with septic shock, 90-day all-cause mortality was lower among those who received hydrocortisone plus fludrocortisone than among those who received placebo. (Funded by Programme Hospitalier de Recherche Clinique 2007 of the French Ministry of Social Affairs and Health; APROCCHSS ClinicalTrials.gov number, NCT00625209 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“In APROCCHSS [478] the dose of vasopressor was ≥ 0.25 µg/kg/min or ≥ 1 mg/h of norepinephrine or epinephrine, or any other vasopressor for at least 6 h to maintain a MAP ≥ 65 mmHg.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationDellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationVincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Self-citationShankar-Hari, M., Phillips, G. S., Levy, M. L., Seymour, C. W., Liu, V. X., Deutschman, C. S., Angus, D. C., Rubenfeld, G. D., Singer, M., & for the Sepsis Definitions Task Force (2016) · JAMA · doi:10.1001/jama.2016.0289 · Cited by 2,424
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Self-citationAnnane, D., Bellissant, E., & Cavaillon, J.-M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17667-8 · Cited by 1,213
Self-citationAnnane, D., Vignon, P., Renault, A., Bollaert, P.-E., Charpentier, C., Martin, C., Troché, G., Ricard, J.-D., Nitenberg, G., Papazian, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61344-0 · Cited by 567
Self-citationCognitive decline after sepsis.
Annane, D., & Sharshar, T. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70246-2 · Cited by 290
Self-citation
Research works printed but not linked: 1
- Guide “100 recommandations pour la surveillance et la préventions des infections nosocomiales.” Bulletin Epidémiologique Hebdomadaire. No. 48. November 30 1992 (http://invs.santepubliquefrance.fr/beh/1992/48/index.html).
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Panchal, A. R., Bartos, J. A., Cabañas, J. G., Donnino, M. W., Drennan, I. R., Hirsch, K. G., Kudenchuk, P. J., Kurz, M. C., Lavonas, E. J., Morley, P. T., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000916 · Cited by 2,105
Cecconi, M., Evans, L., Levy, M., & Rhodes, A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30696-2 · Cited by 2,254
“123 A restrictive haemoglobin target of 7 g/dL is appropriate for non-bleeding patients without active myocardial ischaemia.”
BackgroundClinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Russell, C. D., Millar, J. E., & Baillie, J. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30317-2 · Cited by 2,008
“21, 22 In this group, there is potential that net benefit might be derived from steroid treatment in severe shock.”
Topjian, A. A., Raymond, T. T., Atkins, D., Chan, M., Duff, J. P., Joyner, B. L., Lasa, J. J., Lavonas, E. J., Levy, A., Mahgoub, M., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000901 · Cited by 1,258
Weiss, S. L., Peters, M. J., Alhazzani, W., Agus, M. S. D., Flori, H. R., Inwald, D. P., Nadel, S., Schlapbach, L. J., Tasker, R. C., Argent, A. C., et al. (2020) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000002198 · Cited by 1,228
Sepsis associated acute kidney injury
Poston, J. T., & Koyner, J. L. (2019) · BMJ · doi:10.1136/bmj.k4891 · Cited by 818
Weiss, S. L., Peters, M. J., Alhazzani, W., Agus, M. S. D., Flori, H. R., Inwald, D. P., Nadel, S., Schlapbach, L. J., Tasker, R. C., Argent, A. C., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05878-6 · Cited by 606
Sepsis—Pathophysiology and Therapeutic Concepts
Jarczak, D., Kluge, S., & Nierhaus, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.628302 · Cited by 453
“03) in favor of intervention when hydrocortisone plus fludrocortisone was used in adult septic shock patients, but the study population differed from the first cohort with a lower proportion of surgical patients, abdominal infections and a higher proportion of renal replacement procedures (167).”
ResultEvans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005357 · Cited by 513
Hydrocortisone in Severe Community-Acquired Pneumonia
Dequin, P.-F., Meziani, F., Quenot, J.-P., Kamel, T., Ricard, J.-D., Badie, J., Reignier, J., Heming, N., Plantefève, G., Souweine, B., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215145 · Cited by 468
Self-citationBloodstream infections in critically ill patients: an expert statement
Timsit, J.-F., Ruppé, E., Barbier, F., Tabah, A., & Bassetti, M. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05950-6 · Cited by 448
Self-citationAngus, D. C., Berry, S., Lewis, R. J., Al-Beidh, F., Arabi, Y., van Bentum-Puijk, W., Bhimani, Z., Bonten, M., Broglio, K., Brunkhorst, F., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202003-192sd · Cited by 446
Fujii, T., Luethi, N., Young, P. J., Frei, D. R., Eastwood, G. M., French, C. J., Deane, A. M., Shehabi, Y., Hajjar, L. A., Oliveira, G., et al. (2020) · JAMA · doi:10.1001/jama.2019.22176 · Cited by 466
Meyer, N. J., & Prescott, H. C. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2403213 · Cited by 395
Sepsis and Septic Shock – Basics of diagnosis, pathophysiology and clinical decision making
Font, M. D., Thyagarajan, B., & Khanna, A. K. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.02.011 · Cited by 420
“The APROCCHSS trial showed modest mortality benefit with the administration of bolus-dose hydrocortisone every 6 hours along with a daily administration of oral fludrocortisone.(70)”
BackgroundPrognostic and predictive enrichment in sepsis
Stanski, N. L., & Wong, H. R. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0199-3 · Cited by 393
“Unfortunately, several large clinical trials reported competing conclusions regarding the benefit and safety of corticosteroids in septic shock 45, 46, [52] [53] [54] [55] [56] making it difficult to translate the results of those trials to the bedside.”
BackgroundReappraisal of Ventilator-Free Days in Critical Care Research
Yehya, N., Harhay, M. O., Curley, M. A. Q., Schoenfeld, D. A., & Reeder, R. W. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-2050cp · Cited by 385
Antcliffe, D. B., Burnham, K. L., Al-Beidh, F., Santhakumaran, S., Brett, S. J., Hinds, C. J., Ashby, D., Knight, J. C., & Gordon, A. C. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1419oc · Cited by 365
A druggable copper-signalling pathway that drives inflammation
Solier, S., Müller, S., Cañeque, T., Versini, A., Mansart, A., Sindikubwabo, F., Baron, L., Emam, L., Gestraud, P., Pantoș, G. D., et al. (2023) · Nature · doi:10.1038/s41586-023-06017-4 · Cited by 330
Self-citation2023 Update on Sepsis and Septic Shock in Adult Patients: Management in the Emergency Department
Guarino, M., Perna, B., Cesaro, A. E., Maritati, M., Spampinato, M. D., Contini, C., & De Giorgio, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093188 · Cited by 294
The Global Burden of Sepsis and Septic Shock
La Via, L., Sangiorgio, G., Stefani, S., Marino, A., Nunnari, G., Cocuzza, S., La Mantia, I., Cacopardo, B., Stracquadanio, S., Spampinato, S., et al. (2024) · Epidemiologia · doi:10.3390/epidemiologia5030032 · Cited by 258
Immune dysregulation in sepsis: experiences, lessons and perspectives
Cao, M., Wang, G., & Xie, J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01766-7 · Cited by 259
“Combining hydrocortisone with fl udrocortisone signi fi cantly reduced 90-day all-cause mortality in patients with septic shock [45].”
BackgroundCorticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis
Chaudhuri, D., Sasaki, K., Karkar, A., Sharif, S., Lewis, K., Mammen, M. J., Alexander, P., Ye, Z., Lozano, L. E. C., Munch, M. W., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06394-2 · Cited by 299
“Although there are a number of randomized control trials (RCTs) [2, 3] that have shown benefit of corticosteroids in ARDS, *Correspondence: rochwerg@mcmaster.”
BackgroundSelf-citationFerroptosis and Necroptosis in the Kidney
Belavgeni, A., Meyer, C., Stumpf, J., Hugo, C., & Linkermann, A. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.03.016 · Cited by 275
Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis
Rochwerg, B., Oczkowski, S. J., Siemieniuk, R. A. C., Agoritsas, T., Belley-Cote, E., D’Aragon, F., Duan, E., English, S., Gossack-Keenan, K., Alghuroba, M., et al. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003262 · Cited by 258
Self-citationChaudhuri, D., Nei, A. M., Rochwerg, B., Balk, R. A., Asehnoune, K., Cadena, R., Carcillo, J. A., Correa, R., Drover, K., Esper, A. M., et al. (2024) · Critical Care Medicine · doi:10.1097/ccm.0000000000006172 · Cited by 243
Self-citationMoskowitz, A., Huang, D. T., Hou, P. C., Gong, J., Doshi, P. B., Grossestreuer, A. V., Andersen, L. W., Ngo, L., Sherwin, R. L., Berg, K. M., et al. (2020) · JAMA · doi:10.1001/jama.2020.11946 · Cited by 253
Sepsis and septic shock: Guideline-based management
Dugar, S., Choudhary, C., & Duggal, A. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.18143 · Cited by 229
Vasopressor therapy in critically ill patients with shock
Russell, J. A. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05801-z · Cited by 226
Busse, L. W., Barker, N., & Petersen, C. (2020) · Critical Care · doi:10.1186/s13054-020-2743-8 · Cited by 222
Sepsis-associated encephalopathy and septic encephalitis: an update
Tauber, S. C., Djukic, M., Gossner, J., Eiffert, H., Brück, W., & Nau, R. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1812384 · Cited by 228
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Journal of Intensive Care · doi:10.1186/s40560-021-00555-7 · Cited by 224
Vincent, J.-L. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104318 · Cited by 208
Rygård, S. L., Butler, E., Granholm, A., Møller, M. H., Cohen, J., Finfer, S., Perner, A., Myburgh, J., Venkatesh, B., & Delaney, A. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5197-6 · Cited by 211
Lansbury, L. E., Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J., & Shen Lim, W. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004093 · Cited by 207
Sepsis and septic shock: current approaches to management
Thompson, K., Venkatesh, B., & Finfer, S. (2019) · Internal Medicine Journal · doi:10.1111/imj.14199 · Cited by 190
Current use of vasopressors in septic shock
Scheeren, T. W. L., Bakker, J., De Backer, D., Annane, D., Asfar, P., Boerma, E. C., Cecconi, M., Dubin, A., Dünser, M. W., Duranteau, J., et al. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0498-7 · Cited by 192
Self-citationCorticosteroids as adjunctive therapy in the treatment of influenza
Lansbury, L., Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J., & Lim, W. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010406.pub3 · Cited by 193
“Annane 2018 Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, et al. Hydrocortisone plus fludrocortisone for adults with septic shock.”
BackgroundManagement of pneumonia in critically ill patients
Cillóniz, C., Torres, A., & Niederman, M. S. (2021) · BMJ · doi:10.1136/bmj-2021-065871 · Cited by 171
Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic
Prescott, H. C., & Rice, T. W. (2020) · JAMA · doi:10.1001/jama.2020.16747 · Cited by 196
Kochanek, M., Schalk, E., von Bergwelt-Baildon, M., Beutel, G., Buchheidt, D., Hentrich, M., Henze, L., Kiehl, M., Liebregts, T., von Lilienfeld-Toal, M., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03622-0 · Cited by 188
Challenges in severe community-acquired pneumonia: a point-of-view review
Torres, A., Chalmers, J. D., Dela Cruz, C. S., Dominedò, C., Kollef, M., Martin-Loeches, I., Niederman, M., & Wunderink, R. G. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05519-y · Cited by 177
Fang, F., Zhang, Y., Tang, J., Lunsford, L. D., Li, T., Tang, R., He, J., Xu, P., Faramand, A., Xu, J., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.5849 · Cited by 184
Corticosteroids for treating sepsis in children and adults
Annane, D., Bellissant, É., Bollaert, P. E., Briegel, J., Keh, D., Kupfer, Y. Y., Pirracchio, R., & Rochwerg, B. N. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002243.pub4 · Cited by 200
Self-citationNakamori, Y., Park, E. J., & Shimaoka, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624279 · Cited by 163
“The APROCCHS (Activated Protein C and Corticosteroid for Human Septic Shock) trail, which compared activated protein C, low does corticosteroid, their combination, and placebo, demonstrated that sepsis patients treated with corticosteroid showed a significantly improved 90-day mortality rate (29), while the ADRENAL (A…”
BackgroundKarvellas, C. J., Bajaj, J. S., Kamath, P. S., Napolitano, L. M., O’Leary, J. G., Solà, E., Subramanian, R., Wong, F. S.-H., & Asrani, S. K. (2023) · Hepatology · doi:10.1097/hep.0000000000000671 · Cited by 199
Management of sepsis and septic shock in the emergency department
Gavelli, F., Castello, L. M., & Avanzi, G. C. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02735-7 · Cited by 161
“In 2018, the results from two large RCTs were published, namely ADRENAL and APROCCHSS [91, 97].”
BackgroundInfluentialNew insights into the cell- and tissue-specificity of glucocorticoid actions
Quatrini, L., & Ugolini, S. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00526-2 · Cited by 164
Corticosteroids in Acute Lung Injury: The Dilemma Continues
Mokra, D., Mikolka, P., Kosutova, P., & Mokry, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194765 · Cited by 166
“Contrary, double-blind RCT including adult patients with severe sepsis (n = 190 CS-treated and n = 190 placebo) showed that hydrocortisone at a dose of 200 mg given as a continuous infusion for five days followed by dose tapering until day 11 did not reduce the risk of septic shock within 14 days nor reduced mortality…”
BackgroundMethodHwang, S. Y., Ryoo, S. M., Park, J. E., Jo, Y. H., Jang, D., Suh, G. J., Kim, T., Kim, Y., Kim, S., Cho, H., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06191-3 · Cited by 176
Redefining the perioperative stress response: a narrative review
Manou-Stathopoulou, V., Korbonits, M., & Ackland, G. L. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.08.011 · Cited by 148
Moskowitz, A. L., Andersen, L. W., Huang, D. T., Berg, K. M., Grossestreuer, A. V., Marik, P. E., Sherwin, R. L., Hou, P. C., Becker, L. B., Cocchi, M. N., et al. (2018) · Critical Care · doi:10.1186/s13054-018-2217-4 · Cited by 169
Intra-abdominal sepsis: new definitions and current clinical standards
Hecker, A., Reichert, M., Reuß, C. J., Schmoch, T., Riedel, J. G., Schneck, E., Padberg, W. M., Weigand, M. A., & Hecker, M. (2019) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-019-01752-7 · Cited by 178
Adrenal function and dysfunction in critically ill patients
Téblick, A., Peeters, B., Langouche, L., & den Berghe, G. V. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0185-7 · Cited by 173
“…Time to shock reversal: shorter in GC group Hyperglycaemia, hypernatraemia and superinfections (new sepsis and new septic shock): more in GC group Annane, 2018, APROCCHSS114 1,241 patients with probable or proven septic shock; various inclusion and exclusion criteria Hydrocortisone 50 mg IV…”
BackgroundThe Immune System in Cushing’s Syndrome
Hasenmajer, V., Sbardella, E., Sciarra, F., Minnetti, M., Isidori, A. M., & Venneri, M. A. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.04.004 · Cited by 147
Santacruz, C. A., Pereira, A. J., Celis, É., & Vincent, J. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000004000 · Cited by 160
“Annane et al (9) Sepsis Hydrocortisone + fludrocortisone Placebo”
BackgroundImmune Effects of Corticosteroids in Sepsis
Heming, N., Sivanandamoorthy, S., Meng, P., Bounab, R., & Annane, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01736 · Cited by 153
“Finally, it remains unclear whether or not part of the survival benefit from corticosteroids observed in the GERINF05 (15) and APROCCHSS (16) trials are directly related to fludrocortisone.”
BackgroundSelf-citationLaterre, P.-F., Berry, S. M., Blemings, A., Carlsen, J. E., François, B., Graves, T., Jacobsen, K., Lewis, R. J., Opal, S. M., Perner, A., et al. (2019) · JAMA · doi:10.1001/jama.2019.14607 · Cited by 147
Self-citationZhang, Z., Zhang, G., Goyal, H., Mo, L., & Hong, Y. (2018) · Critical Care · doi:10.1186/s13054-018-2279-3 · Cited by 160
Severe community-acquired pneumonia
Niederman, M. S., & Torres, A. (2022) · European Respiratory Review · doi:10.1183/16000617.0123-2022 · Cited by 157
Corticosteroid therapy for sepsis: a clinical practice guideline
Lamontagne, F., Rochwerg, B., Lytvyn, L., Guyatt, G. H., Møller, M. H., Annane, D., Kho, M. E., Adhikari, N. K. J., Machado, F., Vandvik, P. O., et al. (2018) · BMJ · doi:10.1136/bmj.k3284 · Cited by 125
Self-citationMarik, P. E. (2018) · Nutrients · doi:10.3390/nu10111762 · Cited by 139
“In 2018, two large randomized controlled trials (RCTs) were published evaluating the role of hydrocortisone in patients with septic shock [100,101].”
BackgroundVasopressors in septic shock: which, when, and how much?
Shi, R., Hamzaoui, O., Vita, N. D., Monnet, X., & Teboul, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.04.24 · Cited by 143
“The question of adding low-doses corticosteroids (hydrocortisone) is still a matter of debate (74,75) as its influence on mortality is controversial.”
Glucocorticoids in Sepsis: To Be or Not to Be
Vandewalle, J., & Libert, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01318 · Cited by 132
Yealy, D. M., Mohr, N. M., Shapiro, N. I., Venkatesh, A. K., Jones, A. E., & Self, W. H. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.02.006 · Cited by 136
Diagnostic and therapeutic approach to infectious diseases in solid organ transplant recipients
Timsit, J., Sonneville, R., Kalil, A. C., Bassetti, M., Ferrer, R., Jaber, S., Lanternier, F., Luyt, C. E., Machado, F. S., Mikulska, M., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05597-y · Cited by 124
“Hydrocortisone should be considered in all septic SOT recipients on corticosteroids before ICU admission to avoid adrenal insufficiency [65] .”
BackgroundSelf-citationGirardis, M., David, S., Ferrer, R., Helms, J., Juffermans, N. P., Martín‐Loeches, I., Póvoa, P. M. S. R., Russell, L., Shankar‐Hari, M., Iba, T., et al. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07586-2 · Cited by 133
“The effects of low doses of hydrocortisone in patients with septic shock have been evaluated in several RCTs with variable results [83, 84].”
Yarnell, C. J., Abrams, D. C., Baldwin, M. R., Brodie, D., Fan, E., Ferguson, N. D., Hua, M. S., Madahar, P., McAuley, D. F., Munshi, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30471-9 · Cited by 123
“…trials showing potential benefit in both Bayesian and frequentist analyses across all priors were the Guérin 2013 trial of proning in ARDS39 and the Annane 2018 trial of hydrocortisone with fludrocortisone in septic shock.40 Sensitivity analyses using alternative clinical thresholds (“any benefit”…”
MethodIsidori, A. M., Arnaldi, G., Boscaro, M., Falorni, A., Giordano, C. S. D. S., Giordano, R., Pivonello, R., Pofi, R., Hasenmajer, V., Venneri, M. A., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01266-w · Cited by 119
Fujii, T., Salanti, G., Belletti, A., Bellomo, R., Carr, A. C., Furukawa, T. A., Luethi, N., Luo, Y., Putzu, A., Sartini, C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06558-0 · Cited by 118
“Oneyear mortality was reported in two trials [30, 31]; 180day mortality, four trials [1, 9, 32, 36]; 90-day mortality, four trials [4, 33–35]; 30-day mortality, two trials [3, 37]; 28-day mortality, 15 trials [2, 7, 38–50]; 6-day mortality, one trial[51]; in-hospital mortality, four trials [13, 52–54]; ICU mortality,…”
Corticosteroid use and intensive care unit-acquired weakness: a systematic review and meta-analysis
Yang, T., Li, Z., Jiang, L., & Xi, X. (2018) · Critical Care · doi:10.1186/s13054-018-2111-0 · Cited by 110
Liu, S., Wang, X., She, F., Zhang, W., Liu, H., & Zhao, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.639735 · Cited by 135
“Septic shock is characterized by uncontrolled host response to infections, as the severe form and main cause of death of sepsis (49).”
BackgroundBouras, M., Asehnoune, K., & Roquilly, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02590 · Cited by 107
“, DCs not derived from monocytes) during and after sepsis, and will highlight the effects of glucocorticoids which are the first efficient immunotherapy in severe sepsis (20).”
BackgroundSelf-citationSepsis: a failing starvation response
Vandewalle, J., & Libert, C. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.01.006 · Cited by 109
Trained immunity: induction of an inflammatory memory in disease
Schlüter, T., van Elsas, Y., Priem, B., Ziogas, A., & Netea, M. G. (2025) · Cell Research · doi:10.1038/s41422-025-01171-y · Cited by 114
Vasopressor Therapy in the Intensive Care Unit
Russell, J. A., Gordon, A. C., Williams, M. D., Boyd, J. H., Walley, K. R., & Kissoon, N. “. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1710320 · Cited by 110
Sepsis subphenotypes, theragnostics and personalized sepsis care
Antcliffe, D. B., Burrell, A. J. C., Boyle, A. J., Gordon, A. C., McAuley, D. F., & Silversides, J. A. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-07873-6 · Cited by 110
Shapeton, A. D., Mahmood, F. U., & Ortoleva, J. P. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2018.08.017 · Cited by 95
Challenges in the management of septic shock: a narrative review
Backer, D. D., Cecconi, M., Lipman, J., Machado, F. R., Myatra, S. N., Ostermann, M., Perner, A., Teboul, J., Vincent, J., & Walley, K. R. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05544-x · Cited by 102
Dellinger, R. P., Rhodes, A., Evans, L., Alhazzani, W. A., Beale, R. J., Jaeschke, R., Machado, F. R., Masur, H., Osborn, T. M., Parker, M. M., et al. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005804 · Cited by 105
Towards personalized medicine: a scoping review of immunotherapy in sepsis
Slim, M. A., van Mourik, N., Bakkerus, L., Fuller, K., Acharya, L. S., Giannidis, T., Dionne, J. C., Oczkowski, S. J. W., Netea, M. G., Pickkers, P., et al. (2024) · Critical Care · doi:10.1186/s13054-024-04964-6 · Cited by 96
Invasive Meningococcal Disease in the Vaccine Era
Nadel, S., & Ninis, N. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00321 · Cited by 99
“A recently published study suggests that hydrocortisone together with fludrocortisone may confer a survival benefit in adults with septic shock (22).”
BackgroundEgi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Acute Medicine & Surgery · doi:10.1002/ams2.659 · Cited by 96
Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes
Weiss, S. L., & Fitzgerald, J. C. (2023) · PEDIATRICS · doi:10.1542/peds.2023-062967 · Cited by 100
Expert statement for the management of hypovolemia in sepsis
Perner, A., Cecconi, M., Cronhjort, M., Darmon, M., Jakob, S. M., Pettilä, V., & van der Horst, I. C. C. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5177-x · Cited by 97
Litwak, J., Cho, N. H., Nguyen, H., Moussavi, K., & Bushell, T. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040478 · Cited by 85
“demonstrated its mortality benefits in septic shock patients in two different randomized controlled trials [30,31].”
BackgroundThe End of “One Size Fits All” Sepsis Therapies: Toward an Individualized Approach
Vincent, J., van der Poll, T., & Marshall, J. C. (2022) · Biomedicines · doi:10.3390/biomedicines10092260 · Cited by 91
“The administration of hydrocortisone to patients with severe septic shock was associated with reduced 90-day mortality [16] and is recommended in recent guidelines [17].”
BackgroundMeduri, G. U., & Chrousos, G. P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00161 · Cited by 84
“The inclusion or exclusion of fludrocortisone, as a cointervention with hydrocortisone, may partly explain the differences reported in outcomes of some RCTs (see explanation for Figure 7 below) (292, 298).”
BackgroundResultGlucocorticoids and the Brain after Critical Illness
Hill, A. R., & Spencer-Segal, J. L. (2021) · Endocrinology · doi:10.1210/endocr/bqaa242 · Cited by 90
Combined glucocorticoid resistance and hyperlactatemia contributes to lethal shock in sepsis
Vandewalle, J., Timmermans, S., Paakinaho, V., Vancraeynest, L., Dewyse, L., Vanderhaeghen, T., Wallaeys, C., Wyngene, L. V., Looveren, K. V., Nuyttens, L., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.002 · Cited by 84
Bosch, N. A., Teja, B. J., Law, A. C., Pang, B., Jafarzadeh, S. R., & Walkey, A. J. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.0258 · Cited by 91
Patient-Level Meta-Analysis of Low-Dose Hydrocortisone in Adults with Septic Shock
Pirracchio, R., Annane, D., Waschka, A. K., Lamontagne, F., Arabi, Y. M., Bollaert, P., Billot, L., Du, B., Briegel, J., Cohen, J., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300034 · Cited by 85
Self-citationPeeters, B., Meersseman, P., Vander Perre, S., Wouters, P. J., Vanmarcke, D., Debaveye, Y., Billen, J., Vermeersch, P., Langouche, L., & Van den Berghe, G. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5366-7 · Cited by 74
A review of gut failure as a cause and consequence of critical illness
Soranno, D. E., Coopersmith, C. M., Brinkworth, J. F., Factora, F. N., Muntean, J. H., Mythen, M. G., Raphael, J., Shaw, A., Vachharajani, V., & Messer, J. S. (2025) · Critical Care · doi:10.1186/s13054-025-05309-7 · Cited by 82
Refractory septic shock: our pragmatic approach
Nandhabalan, P., Ioannou, N., Meadows, C. I. S., & Wyncoll, D. L. A. (2018) · Critical Care · doi:10.1186/s13054-018-2144-4 · Cited by 82
Community-acquired pneumonia as an emergency condition
Cillóniz, C., Dominedò, C., García‐Vidal, C., & Torres, A. (2018) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000550 · Cited by 76
“CORTICOSTEROIDS IN SEPTIC SHOCK Two recent RCTs [10,11]evaluated the role of hydrocortisone in patients with septic shock, reporting conflicting results.”
ResultLymphopenia in sepsis—an acquired immunodeficiency?
Finfer, S. R., Venkatesh, B., Hotchkiss, R. S., & Sasson, S. C. (2022) · Immunology and Cell Biology · doi:10.1111/imcb.12611 · Cited by 77
“The APROCCHSS study assessed the effect of hydrocortisone and fludrocortisone on all-cause mortality at 90 days in patients diagnosed with septic shock within 24 h of intensive care unit (ICU) admission.(6) Here, treatment reduced mortality at 90 days (43% versus 49%); however, this finding was not confirmed in the AD…”
BackgroundHager, D. N., Hooper, M. H., Bernard, G. R., Busse, L. W., Ely, E. W., Fowler, A. A., Gaieski, D. F., Hall, A. J., Hinson, J. S., Jackson, J. C., et al. (2019) · Trials · doi:10.1186/s13063-019-3254-2 · Cited by 77
Metadata
- Authors
- Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J.-P., Siami, S., Cariou, A., Forceville, X., Schwebel, C., Martin, C., Timsit, J.-F., Misset, B., Ali Benali, M., Colin, G., Souweine, B., Asehnoune, K., Mercier, E., Chimot, L., Charpentier, C., François, B., Boulain, T., Petitpas, F., Constantin, J.-M., Dhonneur, G., Baudin, F., Combes, A., Bohé, J., Loriferne, J.-F., Amathieu, R., Cook, F., Slama, M., Leroy, O., Capellier, G., Dargent, A., Hissem, T., Maxime, V., & Bellissant, E.
- Affiliations
- Inserm (FR)
- From Service de Médecine Intensive et Réanimation, Hôpital Raymond Poincaré, Garches (D.A., V.M.), Laboratory of Infection and Inflammation Unité 1173, University of Versailles Saint-Quentin-en-Yvelines, INSERM, Montigny-le-Bretonneux (D.A.), Service de Pharmacologie Clinique–Centre d’Investigation Clinique (CIC) INSERM 1414, Centre Hospitalier Universitaire (CHU) de Rennes–Université de Rennes 1, Hôpital Pontchaillou, Rennes (A.R., E.B.), Service de Réanimation Médicale (C.B.-B.) and Service...
- ORCID
- Annane, Djillali
- Renault, Alain
- Quenot, Jean-Pierre
- Siami, Shidasp
- Cariou, Alain
- Forceville, Xavier
- Schwebel, Carole
- Misset, Benoît
- Souweine, Bertrand
- Asehnoune, Karim
- François, Bruno
- Boulain, Thierry
- Constantin, Jean-Michel
- Combes, Alain
- Bohé, Julien
- Amathieu, Roland
- Cook, Fabrice
- Slama, Michel
- Capellier, Gilles
- Dargent, Auguste
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 809-818
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2794125559
- Cited by
- 939
- References
- 22
- Citations by year
- 2026: 107 · 2025: 104 · 2024: 97 · 2023: 115 · 2022: 101 · 2021: 98 · 2020: 121 · 2019: 123 · 2018: 70
- FWCI
- 80.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Funders
- Ministère des Affaires Sociales et de la Santé (Programme Hospitalier de Recherche Clinique / P 07)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- cortisol, fludrocortisone, drotrecogin alfa (activated), corticosteroid therapy, host response to infection, 90-day mortality, vasopressor-free days, organ failure, mechanical ventilation, intensive care unit discharge, sepsis treatment
- MeSH terms
- Simplified Acute Physiology Score, Aged, Anti-Inflammatory Agents, Cause of Death, Combined Modality Therapy, Double-Blind Method, Drug Therapy, Combination, Female, Fludrocortisone, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Analysis, Treatment Outcome, Renal Replacement Therapy, Organ Dysfunction Scores
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.